Safety and Efficacy of LEE011 and LGX818 in Patients With BRAF Mutant Melanoma.

NCT01777776 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

TERMINATED

Status

28

Enrollment

INDUSTRY

Sponsor class

Stopped Study was withdrawn due to scientific and business considerations.

Conditions

Locally Advanced Metastatic BRAF Mutant Melanoma

Interventions

DRUG: LEE011
DRUG: LGX818

Sponsor

Array BioPharma